Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Episodic and Chronic Cluster Headache: Differences in Family History, Traumatic Head Injury, and Chronorisk

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

OBJECTIVE: To investigate whether intravenously infused provokes migraine aura and migraine headache in migraine patients with aura.

BACKGROUND: Migraine with aura has been associated with endothelial dysfunction and increased stroke risk. The initiating mechanism of migraine aura symptoms is not known. Experimental provocation of migraine headache using vasoactive peptides has provided tremendous advances in the understanding of migraine pathophysiology but substances that can induce migraine aura have not been identified. Endothelin-1 (ET-1), an endogenous, potent vasoconstrictor peptide released from the vascular endothelium, has been proposed to trigger migraine aura. This hypothesis is based on reports of increased plasma ET-1 levels early during the migraine attacks and the observation that ET-1 applied to the cortical surface potently induces the cortical spreading depolarization, the underlying electrophysiological phenomenon of migraine aura, in animals. Further, endothelial damage due to, for example, carotid puncture and vascular pathology is known to trigger aura episodes.

METHODS: We investigated whether intravascular ET-1 would provoke migraine aura in patients. Using a two-way crossover, randomized, placebo-controlled, double-blind design, we infused high-dose (8 ng/kg/minutes for 20 minutes) intravenous ET-1 in patients with migraine with typical aura. The primary end-point was the difference in incidence of migraine aura between ET-1 and placebo. Experiments were carried out at a public tertiary headache center (Danish Headache Center, Rigshospitalet Glostrup, Denmark).

RESULTS: Fourteen patients received intravenous ET-1. No patients reported migraine aura symptoms or migraine headache during or up to 24 hours following the ET-1 infusion. Four patients reported mild to moderate headache only on the ET-1 day, 3 patients reported moderate headache on the placebo day, and 1 patient reported mild headache on both days. No serious adverse events occurred during or after infusion.

CONCLUSIONS: Provocation of migraine aura by procedures or conditions involving vascular irritation is unlikely to be mediated by ET-1.

Original languageEnglish
JournalHeadache
Volume60
Issue number4
Pages (from-to)724-734
Number of pages11
ISSN0017-8748
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • endothelium, human, provocation, trigger, vascular

ID: 59482976